Asieris Pharmaceuticals, a China-based biotech company, has received approval for its Phase I clinical trial of APL-1501 from the Australian regulatory authorities, it was reported on Wednesday.
The aim of this Phase I study is to assess APL-1501's safety, tolerability, and pharmacokinetic characteristics for the treatment of non-muscle invasive bladder cancer (NMIBC).
The product has been independently developed by the company's Prodrug Accurate Drug Delivery platform and is an oral sustained-release product based on APL-1202 and will be the second-generation product of APL-1202 to support new clinical development globally. It inherits the oral administration of APL-1202 and the druggability of APL-1501 and has been improved by the design of prodrug molecules.
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Privo Technologies reports progress in oral cancer trial
Astellas to present VEOZAH (fezolinetant) data at Menopause Society 2025 Annual Meeting
Imaging Biometrics acquires Kirkstall to expand presence in advanced cell culture technologies
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference